More recently, a study has demonstrated that VEGF‐C156S treatment exerts multifaceted therapeutic effects to attenuate angiotensin II‐induced cardiac dysfunction by improving cardiac lymphatic function and reducing cardiac fibrosis, inflammation, and arterial hypertension.52 The gene discussed is AGT; the disease is fibrosis.